Aligning with current clinical practice guidance, it is the consensus of this committee that a yearly measurement of BNP or NT-proBNP be assessed in individuals at higher risk for incident HF, such as those with LVH, CKD or T2DM. Here, NPPB is linked to type 2 diabetes mellitus.